Alzheimer’s & Parkinson’s Drug Development Summit 2025

March 18-20, 2025
Boston, MA

The 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit, taking place March 18-20, 2025, in Boston, MA, will bring together over 150 experts from biotech, pharma, and academia to drive innovation in neurodegenerative therapies. With a spotlight on emerging targets like NLRP3 and GBA, the summit will highlight advancements in α-synuclein detection, blood-based biomarkers, and novel approaches that go beyond traditional amyloid-beta strategies.

This premier industry event covers the entire drug development spectrum — from early discovery to late-stage clinical trials and regulatory pathways — and features insights from leading organizations such as Eisai, Eli Lilly, Biogen, and Roche. Key discussions will focus on enabling presymptomatic diagnosis, addressing disease complexity, and accelerating the development of transformative treatments for Alzheimer’s and Parkinson’s diseases.

As a trusted CRO partner for Alzheimer’s and Parkinson’s clinical trials, PRC Clinical collaborates with sponsors to enhance patient enrollment and optimize operational efficiency. Contact us today to schedule a meeting and explore how we can support the advancement of your neurodegenerative therapies.

View the Conference Website